Ionis Pharmaceuticals, Inc. (IONS)

Market Cap	5.59B
Revenue (ttm)	803.07M
Net Income (ttm)	-358.81M
Shares Out	157.90M
EPS (ttm)	-2.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,137,690
Open	33.85
Previous Close	33.75
Day's Range	33.53 - 35.60
52-Week Range	33.33 - 54.44
Beta	0.39
Analysts	Buy
Price Target	62.00 (+75.14%)
Earnings Date	Nov 6, 2024

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 1991
• Employees: 927
• Stock Exchange: NASDAQ
• Ticker Symbol: IONS
• Website: https://www.ionispharma.com

Financial Performance

In 2023, Ionis Pharmaceuticals's revenue was $787.65 million, an increase of 34.10% compared to the previous year's $587.37 million. Losses were -$366.29 million, 35.8% more than in 2022.

Analyst Forecast

According to 18 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is $62.0, which is an increase of 75.14% from the latest price.

Price Target

$62.0

(75.14% upside)

Analyst Consensus: Buy